BIOTECH THAWS OUT:
“Small drug discovery firms are capitalizing on the positive momentum that’s returned to the market for biotechnology stocks. A dozen have announced plans this quarter to launch initial public stock offerings (IPOs), while nearly as many more hope to raise money through follow-on bids. The upturn, if it persists, may help rescue a sector where limited cash flow has precipitated major cutbacks and consolidation.”
Suit targets 13 generic drug makers
“Jumping into the escalating legal battle against pharmaceutical manufacturers, Attorney General Thomas F. Reilly planned to file a lawsuit today against 13 generic drug makers, claiming they overcharged the state Medicaid program $50 million for more than 150 medications.”
Judge Allows Antitrust Case Against Seed Producers
“A federal judge on Friday let proceed an antitrust case that accused the Monsanto Company and other big agricultural seed giants of conspiring to control the world’s market in genetically modified crops.”
Definitions Impede Stem-Cell Work
The medical promise of embryonic stem-cell research has been plagued by ethical controversy. Now, an apparent way to get stem cells without destroying human embryos is hung up by federal policy.